JNJ submits paliperidone ER MAA

Johnson & Johnson (JNJ) submitted an MAA to EMEA for paliperidone prolonged release tablets to treat schizophrenia. Last November, JNJ submitted an NDA for paliperidone for the same indication. Palipe...